Various clinical trials have indicated that several pharmacological agents, including angiotensin II receptor blockers (ARBs) or farnesoid X receptor (FXR) agonists, are effective in NASH treatment. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.